EYEN Stock Overview
A commercial-stage ophthalmic pharmaceutical technology company, engages in developing a pipeline of microdose array print therapeutics. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 2 more risks
My Notes
Capture your thoughts, links and company narrative
Eyenovia, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.035 |
| 52 Week High | US$2.57 |
| 52 Week Low | US$0.032 |
| Beta | 1.32 |
| 1 Month Change | -76.30% |
| 3 Month Change | -93.20% |
| 1 Year Change | -98.09% |
| 3 Year Change | -98.82% |
| 5 Year Change | -99.20% |
| Change since IPO | -99.65% |
Recent News & Updates
Shareholder Returns
| EYEN | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -39.4% | 4.2% | -0.5% |
| 1Y | -98.1% | 5.1% | 24.3% |
Return vs Industry: EYEN underperformed the US Pharmaceuticals industry which returned 5.1% over the past year.
Return vs Market: EYEN underperformed the US Market which returned 24.3% over the past year.
Price Volatility
| EYEN volatility | |
|---|---|
| EYEN Average Weekly Movement | 33.5% |
| Pharmaceuticals Industry Average Movement | 10.6% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in US Market | 18.8% |
| 10% least volatile stocks in US Market | 3.3% |
Stable Share Price: EYEN's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: EYEN's weekly volatility has increased from 23% to 33% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | 57 | Michael Rowe | www.eyenovia.com |
Eyenovia, Inc., a commercial-stage ophthalmic pharmaceutical technology company, engages in developing a pipeline of microdose array print therapeutics. It focuses on commercializing Mydcombi (tropicamide and phenylephrine HCL ophthalmic spray) for inducing mydriasis for routine diagnostic procedures and in conditions where short term pupil dilation is desired, and clobetasol propionate ophthalmic suspension for the treatment of post-operative pain and inflammation following ocular surgery. The company is also developing the Optejet delivery system for use in combination with its drug-device therapeutic programs and for out-licensing for use in combination with therapeutics for additional indications.
Eyenovia, Inc. Fundamentals Summary
| EYEN fundamental statistics | |
|---|---|
| Market cap | US$3.89m |
| Earnings (TTM) | -US$37.83m |
| Revenue (TTM) | US$31.83k |
121.1x
P/S Ratio-0.1x
P/E RatioIs EYEN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| EYEN income statement (TTM) | |
|---|---|
| Revenue | US$31.83k |
| Cost of Revenue | US$5.68m |
| Gross Profit | -US$5.65m |
| Other Expenses | US$32.18m |
| Earnings | -US$37.83m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.34 |
| Gross Margin | -17,746.45% |
| Net Profit Margin | -118,845.16% |
| Debt/Equity Ratio | 311.1% |
How did EYEN perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/31 22:25 |
| End of Day Share Price | 2025/01/31 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Eyenovia, Inc. is covered by 7 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jonathan Aschoff | B. Riley Wealth |
| Brian Kemp Dolliver | Brookline Capital Markets |
| Yi Chen | H.C. Wainwright & Co. |